Grace A McComsey, Douglas Kitch, Paul E Sax, Camlin Tierney, Nasreen C Jahed, Kathleen Melbourne, Belinda Ha, Todd T Brown, Anthony Bloom, Neal Fedarko,

Slides:



Advertisements
Similar presentations
DACS 272 Neurologic deficits in the years following ART initiation among subjects in the AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized.
Advertisements

 Exemplary Care  Cutting-edge Research  World-class Education  Raghavan Murugan MD, MS, FRCP Associate Professor Dept. of Critical Care Medicine Clinical.
Comparison of INSTI vs PI  FLAMINGO  GS  ACTG A5257.
April 25 Exam April 27 (bring calculator with exp) Cox-Regression
Protective HLA Class I alleles are associated with reduced immune activation in Primary HIV infection Elizabeth Hamlyn 1, Stephen Hickling 2, Abdel Babiker.
Role of Antiretroviral Therapy, Viral Replication, and HIV Infection in Atherosclerosis Priscilla Y. Hsue, Peter W. Hunt, Jeffrey N. Martin, Amanda Schnell,
Switch to ATV/r monotherapy - ATARITMO - Swedish Study - ACTG A OREY.
Assessing Survival: Cox Proportional Hazards Model Peter T. Donnan Professor of Epidemiology and Biostatistics Statistics for Health Research.
Comparison of PI vs PI  ATV/r vs DRV/rATADAR. ATV/r 300/100 mg + TDF/FTC qd N = 91 N = 89 DRV/r 800/100 mg + TDF/FTC qd  Design Randomisation 1: 1 Open-label.
Introduction DCDOH supports HIV test and treat activities - increased number of HIV tests performed, emphasis on earlier linkage to care. Limited data.
Factors associated with Mortality in the Study of Fat Redistribution and Metabolic Change in HIV infection Leslie Modrich 1, Rebecca Scherzer 1,2, Andrew.
Background There is uncertainty regarding the frequency, predictors, and outcomes of IRIS events Prior studies on IRIS have been limited to convenience.
Switch to TDF/FTC/RPV  SPIRIT Study. SPIRIT study: Switch PI/r + 2 NRTI to TDF/FTC/RPV TDF/FTC/RPV STR 24 weeks 48 weeks Primary Endpoint Secondary Endpoint.
Pablo Tebas, MD.  ACTG 5202/5224s  STARTMRK Metabolic Study  STEAL (abacavir and inflammatory markers)  EUROSIDA and risk of CKD  HOPS and risk of.
Risk of Osteoporotic Fractures Associated with Cumulative Exposure to Tenofovir and Other Antiretroviral Agents Roger Bedimo, MD; Song Zhang, PhD; Henning.
Increased clinical events in HIV-infected patients who achieve full virologic suppression but fail to attain a CD4 count ≥ 200 cells/mm 3 after one year.
Assessing Survival: Cox Proportional Hazards Model
A Phase II, Randomized, Placebo-Controlled Study of Once-Weekly Alendronate in HIV- Infected Subjects with Decreased Bone Mineral Density Receiving Calcium.
NRTI-sparing  SPARTAN  PROGRESS  NEAT001/ANRS 143  MODERN.
Catherine Kober Margaret Johnson Martin Fisher Caroline Sabin On behalf of UK-CHIC BHIVA/BASHH Manchester 2010 Non-uptake of HAART among patients with.
The Interplay of the Osteoprotegerin/RANKL Axis and Dysfunctional HDL in HIV-Infected Adults AIDS Clinical Trials Group Study NWCS 332/A5078 Kelesidis.
Impact of Highly Active Antiretroviral Therapy on the Incidence of HIV- encephalopathy among perinatally- infected children and adolescents. Kunjal Patel,
Poster # 388 CROI Feb Montreal, Canada Association of HIV-1 Co-receptor Tropism with Immunologic and Virologic Parameters in HIV-1 infected,
David Dowdy, Elvin Geng, Katerina Christopoulos, James Kahn, C. Bradley Hare, Daniel Wlodarczyk, Diane Havlir Internal Medicine Residency Program, UCSF.
Comparison of NRTI combinations  ZDV/3TC vs TDF + FTC –Study 934  ABC/3TC vs TDF/FTC –HEAT Study –ACTG A5202 Study –ASSERT Study  FTC/TDF vs FTC/TAF.
Introductory talk D Costagliola.
Long-term Bone Mineral Density Changes in Antiretroviral-treated HIV-Infected Individuals Grant P, Kitch D, McComsey G, Collier A, Koletar S, Erlandson.
A prospective, randomized, Phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection – ACTG 5142 Riddler S.A.,
Comparison of NNRTI vs PI/r  EFV vs LPV/r vs EFV + LPV/r –A5142 –Mexican Study  NVP vs ATV/r –ARTEN  EFV vs ATV/r –A5202.
Supported by: NIAID/NHLBI R24 AI067039, NIAID R21 AI Viremia copy-years: A measure of cumulative HIV burden among patients initiating antiretroviral.
12th Conference on Retroviruses and Opportunistic Infections February 22-25, 2005 Boston, Massachusetts, USA Poster No. 830 Hematological Benefit of Switching.
Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,
Comparison of NNRTI vs PI/r  EFV vs LPV/r vs EFV + LPV/r –A5142 –Mexican Study  NVP vs ATV/r –ARTEN  EFV vs ATV/r –A5202.
NRTI-sparing  SPARTAN  PROGRESS  NEAT001/ANRS 143  MODERN.
THE 6 TH NATIONAL SCIENTIFIC CONFERENCE ON HIV/AIDS Yield and impact of repeated screening for tuberculosis and isoniazid preventive therapy among patients.
Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.
Switch to RAL-containing regimen  Canadian Study  CHEER  Montreal Study  EASIER  SWITCHMRK  SPIRAL  Switch ER.
Comparison of NNRTI vs NNRTI  ENCORE  EFV vs RPV –ECHO-THRIVE –STAR  EFV vs ETR –SENSE.
Comparison of NRTI combinations  ZDV/3TC vs TDF + FTC –Study 934  ABC/3TC vs TDF/FTC –HEAT Study –ACTG A5202 Study –ASSERT Study  FTC/TDF vs FTC/TAF.
Comparison of PI vs PI  ATV vs ATV/r BMS 089  LPV/r mono vs LPV/r + ZDV/3TCMONARK  LPV/r QD vs BIDM M A5073  LPV/r + 3TC vs LPV/r + 2 NRTIGARDEL.
Long-Term Comparison of Nevirapine Versus Efavirenz When Combined with Other Antiretroviral Drugs in HIV-1 Positive Antiretroviral-Naïve Persons- The NNRTI.
Weekly Alendronate Safe and Effective at Increasing Bone Mineral Density in HIV-Infected Persons on Antiretroviral Therapy Slideset on: McComsey GA, Kendall.
For the primary endpoint, the mean eGFR (2012 CKD- EPI Cr-CC) change at 96 weeks was significantly greater for ABC/3TC vs. TDF/FTC (Figure 1). In the
Cutrell A, Hernandez J, Brothers C et al Is abacavir (ABC)-containing combination antiretroviral therapy (CART) associated with myocardial infarction.
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
Efavirenz Use Not Associated With Depressive Episodes, According to Analysis of Randomized Clinical Trial Outcomes Slideset on: Journot V, Chene G, De.
Diego Ripamonti - Malattie Infettive - Bergamo Simposio HOT TOPICS Hot topics in HIV 2015.
Slideset on: Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving.
ACTG 5142: First-line Antiretroviral Therapy With Efavirenz Plus NRTIs Has Greater Antiretroviral Activity Than Lopinavir/Ritonavir Plus NRTIs Slideset.
EPZICOM ® Virologic Response in ART-Naïve Patients with Baseline Viral Loads Above and Below 100,000c/mL Using the A5202 Endpoint K. Pappa, J. Hernandez,
Effects of Switching ZDV-3TC to TDF-FTC or ABC-3TC SWAP
Inflammation Markers and The Risk of Non-AIDS Events
Higher rate of antiretroviral therapy reinitiation among HIV-HBV coinfected patients in the episodic arm of the SMART study Dore G.1, Soriano V.2, Neuhaus.
College of Nursing ● University of Kentucky ● Lexington, KY
Intensification with INSTI
Long-Term Clinical and Immunologic Outcomes Are Similar in HIV-Infected Persons Randomized to NNRTI versus PI versus NNRTI+PI-based Antiretroviral Regimens.
Comparison of NNRTI vs PI/r
Comparison of NRTI combinations
Comparison of NNRTI vs PI/r
Comparison of INSTI vs PI
Switch to RAL-containing regimen
Melissa Herrin, Jan Tate ScD, MPH & Amy Justice, MD, PhD
Comparison of NRTI combinations
Intensification with INSTI
NRTI-sparing SPARTAN PROGRESS RADAR NEAT001/ANRS 143 A VEMAN
Switch to ATV/r monotherapy
Comparison of NRTI combinations
A prospective, randomized, Phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection – ACTG 5142 Riddler S.A.,
Comparison of NNRTI vs NNRTI
DTG + 3TC vs DTG + TDF/FTC GEMINI.
Presentation transcript:

Grace A McComsey, Douglas Kitch, Paul E Sax, Camlin Tierney, Nasreen C Jahed, Kathleen Melbourne, Belinda Ha, Todd T Brown, Anthony Bloom, Neal Fedarko, and Eric S Daar on behalf of the ACTG A5224s team

 Increased inflammation persists on ART and may drive clinical events and mortality  Several studies have found associations between single measurements of selective inflammatory markers and mortality  The purpose of this presentation is to present the associations between inflammatory markers (pre-ART and after ART initiation) and clinical events in a prospective clinical trial A5224s

A5224s design: Metabolic substudy of A5202 A5224s

Significant decreases in TNF- , sTNFR-I, sTNFR-II, sVCAM-1, and sICAM-1 levels within all arms, without differences between ABC/3TC and TDF/FTC or ATV/r and EFV More favorable changes in IL-6 at week 24 and hsCRP at weeks 24 and 96 with TDF/FTC vs. ABC/3TC McComsey, AIDS 2012 A5224s

 Exploratory analysis  To assess the association between baseline and time-updated inflammatory biomarker levels and time to first AIDS-defining and/or non-AIDS-defining events  Cox proportional hazards regression models  Only first event occurring in each category in each subject was used in analysis

N=244 Age years, median (Q1, Q3)39 (31, 44) Male (%)85% White non-Hispanic Race/Ethnicity (%)48% HIV-1 RNA log 10 c/mL, median (Q1, Q3)4.64 (4.26, 4.91) HIV RNA ≥ 100,000 c/mL Stratum (%)41% CD4 cells/mm 3, median (Q1, Q3)240 (106, 335) CD4 < 200 cells/mm 3 (%)43% hsCRP  g/mL, median (Q1, Q3) 1.7 (0.7, 4.0) IL-6 pg/mL, median (Q1, Q3) 0.8 (0.5, 1.4) TNF-α pg/mL, median (Q1, Q3) 11.0 (8.2, 14.7) sTNF-RI pg/mL, median (Q1, Q3) 1277 (1105, 1538) sTNFR-II pg/mL, median (Q1, Q3) 5350 (3965, 7756) sVCAM-1 ng/mL, median (Q1, Q3) 1187 (939, 1599) sICAM-1 ng/mL, median (Q1, Q3) 330 (267, 402) A5224s

Correlations Among Markers at Baseline A5224s Spearman’s rank correlation coefficient

Correlations Among Markers at Week 24 A5224s Spearman’s rank correlation coefficient

Description of Events  AIDS-defining events (CDC classification)  13 events: 9 OIs; 3 AIDS-cancers, 1 recurrent bacterial pneumonia  Events occurred between 2 and 133 weeks, median 16 weeks  Of these, 7 events occurred within first 24 weeks  Non-AIDS events  18 events: 6 diabetes, 4 cancers, 3 cardiovascular, 5 pneumonias  Events occurred between 3.5 and 165 weeks, median 81 weeks  Of these, 4 events occurred within first 24 weeks  AIDS- or Non-AIDS events  28 events  Events occurred between 2 and 164 weeks, median 32 weeks  Of these, 11 events occurred within first 24 weeks A5224s

HR= hazard ratio from Cox Proportional Hazard model

Other Results A5224s

HR= hazard ratio from Cox Proportional Hazard model

 15 (traumatic) fractures occurred  Considered separate from non-AIDS events  Neither baseline nor time-updated biomarker values were significantly associated with an increased risk of fracture

 At baseline, CD4 count correlated with IL6, sTNFR-I and II  Changes in CD4 correlated with changes in TNF- , sTNF-Rs and adhesion molecules  At baseline, HIV-1 RNA correlated with all markers except for hsCRP  Only change (0-24 w) in sTNFR-I level significantly different between suppressed subjects vs. those >50 copies/mL at week 24

 Higher levels of several inflammatory biomarkers were associated independently of CD4 count with increased risk of AIDS and non-AIDS events.  Time-updated levels in markers of TNF-  and/or sTNF receptors were associated with clinical events whereas this was not observed for hsCRP.

 Small number of events  Relatively short follow up  Time-updated for AIDS events driven by early events  Large number of analyses performed  Adjusted analyses to be interpreted with caution (small events n) Larger and longer studies needed to investigate the use of these markers as predictors of clinical endpoints.

Thank yous  Study Participants and ACTG sites  ACTG 5224s team: Douglas Kitch and Camlin Tierney (SDAC), Paul Sax, Eric Daar, Pablo Tebas, Nasreen Jahed, Laurie Myers, Belinda Ha, Kathleen Melbourne, Lynda Szczech, David Currin, Lori Mong-Kryspin  ACTG 5202 team  ACTG and NIH (NIAID) for supporting A5202/5224 studies  GSK and Gilead for supporting inflammatory markers cost A5224s